BMS calls time on brain cancer trial as Opdivo misses second targetBristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of Share XBMS calls time on brain cancer trial as Opdivo misses second targethttps://pharmaphorum.com/news/bms-calls-time-on-brain-cancer-trial-as-opdivo-misses-second-target/
Roche claims EU okay for Herceptin/Perjeta combination PhesgoRoche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta Share XRoche claims EU okay for Herceptin/Perjeta combination Phesgohttps://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bnFrench pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise Share XServier beefs up in cancer, buying Agios’ oncology business for $1.8bnhttps://pharmaphorum.com/news/servier-cancer-agios-oncology/
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
AZ’s Tagrisso gets new early lung cancer use in USAstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its Share XAZ’s Tagrisso gets new early lung cancer use in UShttps://pharmaphorum.com/news/azs-tagrisso-gets-new-early-lung-cancer-use-in-us/
Merck cuts $1bn deal with Janux for cancer T-cell therapiesIn a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Share XMerck cuts $1bn deal with Janux for cancer T-cell therapieshttps://pharmaphorum.com/news/merck-cuts-1bn-deal-with-janux-for-cancer-t-cell-therapies/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Amgen files KRAS trailblazer sotorasib with FDA for lung cancerAmgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer Share XAmgen files KRAS trailblazer sotorasib with FDA for lung cancerhttps://pharmaphorum.com/news/amgen-files-kras-inhibitor-with-fda/
TG Therapeutics raises funds for cancer combination drugTG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month Share XTG Therapeutics raises funds for cancer combination drughttps://pharmaphorum.com/news/tg-therapeutics-set-for-upsized-ipo-to-develop-cancer-combination-drug/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
UK hospital deploys Microsoft AI to tackle cancer backlogAddenbrooke’s Hospital in Cambridge will be the first in the world to use an artificial intelligence tool developed Share XUK hospital deploys Microsoft AI to tackle cancer backloghttps://pharmaphorum.com/news/uk-hospital-deploys-microsoft-ai-to-tackle-cancer-backlog/
FDA puts Bellicum’s cancer cell therapy trial on holdThe FDA has placed a clinical hold on a phase 1/2 trial of Bellicum’s cancer cell therapy BPX-601, Share XFDA puts Bellicum’s cancer cell therapy trial on holdhttps://pharmaphorum.com/news/fda-puts-bellicums-cancer-cell-therapy-trial-on-hold/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
Exelixis takes $20m option Iconic/Zymeworks’ cancer ADCExelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, Share XExelixis takes $20m option Iconic/Zymeworks’ cancer ADChttps://pharmaphorum.com/news/exelixis-takes-20m-option-iconic-zymeworks-cancer-adc/
